Loading patent…
AssigneesNational University Corporation Tokyo Medical and Dental University, National University Corporation Kumamoto University
InventorHideki Hayashi
Estimating the term…
The present invention provides an agent for neurological disease, the agent comprising lipoprotein containing apolipoprotein E as the active substance thereof, in which a neuroprotective system via activation of neuroprotective molecules and/or the inactivation of neurodegeneration-inducing molecules, mediated by lipoprotein receptors, may work as a mechanism, and a prophylactic and therapeutic method for neurological diseases. The lipoproteins containing apolipoprotein E and/or neuroprotective system through, as the action mechanism, the activation of neuroprotective molecules and the inactivation of neurodegeneration-inducing molecules that are mediated by lipoprotein receptors have prophylactic and therapeutic effects of, including, inhibiting nerve cell apoptosis, on neurological disease such as various neurodegenerative diseases accompanied by nerve cell apoptosis as the essential condition. The invention provides the agent comprising apolipoprotein E-containing lipoproteins and/or having an action mechanism through the activation of neuroprotective molecules and the inactivation of neurodegeneration-inducing molecules that are mediated by lipoprotein receptors.
An inhibitor of a neuroprotective inhibitory effect of α2-macroglobulin for inhibiting the neuroprotective inhibitory effect of α2-macroglobulin by administration onto the eyeball or injection into the eyeball thereof, comprising:
An ophthalmologic composition containing a lipoprotein containing an apolipoprotein E, wherein:
(canceled)
Dependencies are inferred from the claim text.